Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 8/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | KARS1 | Q15046 | 2/20 | 0.32 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | WNT1 | P04628 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3010556 | 0.90 | IGF1R (0.43) | IGF1RGSK3BAURKAKARS1DYRK1A | |
| SCHEMBL3008568 | 0.90 | IGF1R (0.42) | IGF1RGSK3BAURKAMAP3K12DYRK1A | |
| SCHEMBL3011817 | 0.88 | IGF1R (0.45) | IGF1RGSK3BMAPTKARS1DYRK1A | |
| SCHEMBL3010086 | 0.88 | IGF1R (0.41) | IGF1RGSK3BAURKAKARS1MAP3K12 | |
| SCHEMBL11967762 | 0.86 | IGF1R (0.41) | IGF1R | |
| SCHEMBL11967765 | 0.86 | IGF1R (0.41) | IGF1R | |
| SCHEMBL11967751 | 0.85 | IGF1R (0.41) | IGF1RGSK3BMAP3K12DYRK1A | |
| SCHEMBL3000429 | 0.85 | IGF1R (0.41) | IGF1RGSK3BMAP3K12DYRK1A | |
| SCHEMBL3006720 | 0.85 | IGF1R (0.40) | IGF1RGSK3BDYRK1AWNT1PDE10A | |
| SCHEMBL11967763 | 0.85 | IGF1R (0.41) | IGF1RGSK3BAURKAKARS1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415340-B2 | Triazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415340-B2 | Triazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415340-B2 | Triazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2175933-B1 | TRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20100197654-A1 | TRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-05 | — | — | US | disclosed |
| US-20100197654-A1 | TRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-05 | — | — | US | disclosed |
| US-20100197654-A1 | TRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197654-A1 | TRIAZINE KINASE INHIBITORS | ABL1, STK25, FLT3 | IGF1R 688/4885GSK3B 406/4885MAPT 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.